Adverse events of the yellow fever vaccine in chronic urticaria: evaluation of patients treated or not with omalizumab compared to healthy individuals

Almeida, Laura Ramos de; Criado, Roberta Fachini Jardim; Criado, Paulo Ricardo; Ensina, Luis Felipe; Abdalla, Beatrice Martinez Zugaib; Quaresma, Juarez Antônio Simões

doi:10.1016/j.abd.2020.09.009

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AU after COVID-19 vaccination most often occurs after the 1st dose and tends to not recur with subsequent doses. A study including over 49,000 healthcare workers who received mRNA vaccines reported that from 0.4% who developed urticaria after the 1st dose, only 3.3% had a recurrence of urticaria [ 110 , 114 ]. Another study reported that allergic symptoms after the 1st dose of mRNA vaccines may contribute to incomplete vaccination, although out of 1261 with self-reported allergic symptoms after the 1st dose, only 17% had recurrent allergic symptoms at the 2nd dose which were non-severe [ 111 , 115 ].…”

Section: Vaccines and Urticariamentioning

confidence: 99%

“…The safety of the YF vaccine in patients under treatment with omalizumab was also analyzed and those patients did not have a higher rate of adverse events, including CU exacerbations when compared to CU patients treated with antihistamines. In both groups CU was controlled, suggesting that the YF vaccine is safe for CU patients and CU patients treated with omalizumab [ 114 , 117 ].…”

Section: Vaccines and Urticariamentioning

confidence: 99%

See 1 more Smart Citation

How Infection and Vaccination Are Linked to Acute and Chronic Urticaria: A Special Focus on COVID-19

Kocatürk

Muñoz

Elieh‐Ali‐Komi

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

Since more than a century ago, there has been awareness of the connection between viral infections and the onset and exacerbation of urticaria. Our knowledge about the role of viral infection and vaccination in acute and chronic urticaria improved as a result of the COVID-19 pandemic but it has also highlighted knowledge gaps. Viral infections, especially respiratory tract infections like COVID-19, can trigger the onset of acute urticaria (AU) and the exacerbation of chronic urticaria (CU). Less frequently, vaccination against viruses including SARS-CoV-2 can also lead to new onset urticaria as well as worsening of CU in minority. Here, with a particular focus on COVID-19, we review what is known about the role of viral infections and vaccinations as triggers and causes of acute and chronic urticaria. We also discuss possible mechanistic pathways and outline the unmet needs in our knowledge. Although the underlying mechanisms are not clearly understood, it is believed that viral signals, medications, and stress can activate skin mast cells (MCs). Further studies are needed to fully understand the relevance of viral infections and vaccinations in acute and chronic urticaria and to better clarify causal pathways.

show abstract